Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

Rhea-AI Summary

Quanterix (NASDAQ: QTRX) has appointed Dr. Ivana Magovčević-Liebisch to its Board of Directors. With over 25 years of biopharmaceutical industry experience, Dr. Magovčević-Liebisch is the founder, President, and CEO of Vigil Neuroscience. She brings expertise in business development, R&D, and commercialization.

Quanterix CEO Masoud Toloue highlighted the company's Simoa® technology as important for advancing blood-based neuro biomarkers in drug development and clinical trials. Dr. Magovčević-Liebisch expressed excitement about contributing to Quanterix's innovation in ultrasensitive biomarker detection, particularly in the context of emerging therapies for neurodegenerative diseases.

Martin Madaus, Chairman of the Board, emphasized the value of Dr. Magovčević-Liebisch's extensive industry knowledge for Quanterix's expansion into clinical diagnostics.

Positive

• Appointment of Dr. Ivana Magovčević-Liebisch to the Board of Directors, bringing 25+ years of biopharmaceutical industry experience
• Dr. Magovčević-Liebisch's expertise in business development, R&D, and commercialization aligns with Quanterix's growth strategy
• Potential for enhanced partnerships with pharma and biotech companies through Dr. Magovčević-Liebisch's industry connections

Negative

• None.

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors.

Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer’s disease.

Prior to Vigil, Dr. Magovčević-Liebisch was Executive Vice President (EVP) and Chief Business Officer at Ipsen where she was responsible for building the company’s pipeline through executing key strategic transactions. She also served as Senior Vice President and Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. She previously worked at Dyax Corp in management roles including EVP and Chief Operating Officer where she launched the company’s first drug, Kalbitor® for an orphan indication, Hereditary Angioedema, and at Transkaryotic Therapies, Inc. Dr. Magovčević-Liebisch holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology Law from Suffolk University Law School. She graduated from Wheaton College with a B.A. in Biology and Chemistry.

“We are in the early stages of a transformative decade for neurology, with a rapidly growing landscape of therapies that are well positioned to improve patient outcomes. Quanterix’s Simoa® technology is at the forefront of advancing blood-based neuro biomarkers to monitor drug efficacy, improving clinical trials and ultimately regulatory approvals,” said Masoud Toloue, CEO of Quanterix. “Ivana’s business acumen and leadership experience will be invaluable as Quanterix expands its existing biomarker partnerships with pharma and biotech.”

“Quanterix is at the leading edge of ultrasensitive biomarker detection, helping to fuel critical scientific breakthroughs at a time when there is a strong pipeline of therapies for neurodegenerative diseases,” said Dr. Ivana Magovčević-Liebisch. “Joining Quanterix’s Board of Directors presents an exciting opportunity to contribute to continued innovation and advancement in the industry by applying my expertise and experience in biopharmaceutical R&D, intellectual property and regulatory strategy, business development and commercialization.”

“We are excited to have Ivana join our Board and believe her extensive experience and knowledge across multiple aspects of the biopharmaceutical industry will be beneficial as Quanterix continues to expand into clinical diagnostics,” said Martin Madaus Ph.D., Chairman of the Board.

To learn more about Quanterix’s Simoa® technology, visit: https://www.quanterix.com/simoa-technology/.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241002487807/en/

Quanterix Media:

Maya Nimnicht, PAN Communications

(510) 334-6273

pan.quanterix@pancomm.com

Investor Relations:

Francis Pruell, Quanterix

(508) 789-1725

ir@quanterix.com

Source: Quanterix Corporation

FAQ

Who is the new Board member appointed to Quanterix (QTRX)?

Dr. Ivana Magovčević-Liebisch, Ph.D., J.D., has been appointed to Quanterix 's Board of Directors.

What is Dr. Magovčević-Liebisch's background and experience relevant to Quanterix (QTRX)?

Dr. Magovčević-Liebisch has over 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, and has held leadership roles at companies like Ipsen and Teva Pharmaceutical Industries.

How might Dr. Magovčević-Liebisch's appointment benefit Quanterix (QTRX)?

Her expertise in biopharmaceutical R&D, intellectual property, regulatory strategy, business development, and commercialization is expected to contribute to Quanterix's expansion into clinical diagnostics and partnerships with pharma and biotech companies.

What is the significance of Quanterix's (QTRX) Simoa® technology in the context of this appointment?

Simoa® technology is at the forefront of advancing blood-based neuro biomarkers for monitoring drug efficacy and improving clinical trials, which aligns with Dr. Magovčević-Liebisch's experience in neurodegenerative disease therapies.